文献速递肺结节与肺癌

组织活检在肺癌分子检测中仍是关键问题吗?

Is tissue still the issue in detecting molecular alterations in lung cancer?
PubMed 文献 · Respirology · 2020-04-25

本文综述晚期非小细胞肺癌(NSCLC)分子检测中组织活检与液体活检的定位。组织活检仍是初始诊断、组织学分型与分子检测的基础,但小活检和细胞学标本常不足以完成日益增多的预测标志物检测;液体活检通过血浆游离循环肿瘤DNA(ctDNA)无创识别分子改变,有望克服组织活检的局限。

要点

  • 晚期NSCLC分子标志物检测是标准诊疗与靶向治疗前的诊断流程组成部分。
  • 小活检与细胞学标本材料有限,需限制诊断性操作以保留组织用于生物标志物检测。
  • 组织活检受肿瘤异质性限制,尤其在耐药时可能产生假阴性结果。

核心结论

  • 组织活检仍是晚期NSCLC初始诊断、组织学分型与分子检测的必要环节。
  • 液体活检通过血浆ctDNA无创识别分子改变,有望克服组织活检的局限并替代部分重复活检需求。

研究设计与样本

  • 本文为综述,讨论晚期NSCLC分子检测中组织活检与液体活检的应用与局限。

主要发现

  • 许多晚期NSCLC患者组织不足以完成分子检测,和/或无适合活检的病灶,和/或因潜在风险不愿重复活检。
  • 极小块活检标本的有限材料若已用于常规诊断,分子检测可能困难或无法进行。
  • 肿瘤异质性可限制组织活检,尤其在疾病耐药时可能产生假阴性结果。

关键数值与推荐

  • 推荐限制诊断性检查以保留足够组织用于生物标志物检测。
  • 晚期NSCLC的分子生物标志物检测被视为标准诊疗,并作为识别分子靶向治疗患者亚群的诊断流程一部分。

临床怎么用

  • 初始诊断时应合理管理有限的活检与细胞学材料,优先保留组织用于分子检测。
  • 对组织不足或不宜重复活检者,可考虑液体活检ctDNA检测分子改变。

局限性

  • 组织活检受肿瘤异质性限制,尤其在耐药情况下可能假阴性。
  • 小活检与细胞学标本材料有限,可能无法完成日益增多的预测标志物检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular biomarker testing of advanced-stage NSCLC is now considered standard of care and part of the diagnostic algorithm to identify subsets of patients for molecular-targeted treatment. Tumour tissue biopsy is essential for an accurate initial diagnosis, determination of the histological subtype and for molecular testing. With the increasing use of small biopsies and cytological specimens for diagnosis and the need to identify an increasing number of predictive biomarkers, proper management of the limited amount of sampling materials available is important. Many patients with advanced NSCLC do not have enough tissue for molecular testing and/or do not have a biopsy-amenable lesion and/or do not want to go through a repeat biopsy given the potential risks. Molecular testing can be difficult or impossible if the sparse material from very small biopsy specimens has already been exhausted for routine diagnostic purposes. A limited diagnostic workup is recommended to preserve sufficient tissue for biomarker testing. In addition, tumour biopsies are limited by tumour heterogeneity, particularly in the setting of disease resistance, and thus may yield false-negative results. Hence, there have been considerable efforts to determine if liquid biopsy in which molecular alterations can be non-invasively identified in plasma cell-free ctDNA, a potential surrogate for the entire tumour genome, can overcome the issues with tissue biopsies and replace the need for the latter.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Liam CK, Mallawathantri S, Fong KM, et al. Is tissue still the issue in detecting molecular alterations in lung cancer? Respirology. 2020. PMID: 32335992. doi:10.1111/resp.13823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。